Firms will work together to complete Phase II testing.

Kainos Medicines agreed to help Parion Sciences’ advance its epithelial sodium channel blocker, P-552, for the treatment of dry mouth associated with primary Sjogren’s syndrome. Kainos will provide up to $25 million upon completion of all milestones.

The companies will work together up to the Phase II stage. Parion will oversee clinical development, while Kainos will offer chemistry, manufacturing, and controls expertise.

In a Phase I/II clinical completed in April, P-552 was found to be safe and tolerable in subjects with primary Sjogren’s disease. Epithelial sodium channel blockers such as P-552 are being developed to maintain and stimulate hydration on the body’s mucosal surfaces like those of the lung, mouth, nose, eye, and gastrointestinal tract.

Previous articleClinical Data to Take Over Avalon for $10M in Stock
Next articleBattelle to Evaluate IntelligentMDx’ Prognostic Assay for Kidney Transplant Patients